Clinical Study

Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation

Table 1

Clinical effects after one month of Sativex medication. Data are reported as mean ± sd. The asterisk refers to the significant modification at , in comparison to ( < 0.05, < 0.01).

Clinical outcomes

PrimaryMAS4 ± 0.73 ± 0.9
AI7.3 ± 0.56 ± 0.6
NRS8.3 ± 0.55.5 ± 0.4
10 WT (s)98 ± 969 ± 7
10 WT (%)33 ± 853 ± 9

SecondaryPFSF2.8 ± 0.52.2 ± 0.3
MS-QoL112 ± 8119 ± 5
VAS4.4 ± 0.53 ± 0.2
BLCS15 ± 211 ± 1
EDSS6.3 ± 0.26.1 ± 0.2

EDDS: Expanded Disability Scale; MAS: Modified Ashworth Scale; NRS: numerical rating scale; 10 WT: ten-meter walking test in seconds of walk-through (s) and percent of patients able to perform the test (%); AI: Ambulation Index; pVAS: visual analogic scale for chronic pain rating; PSFS: Penn spasm frequency scale; BLCS: bladder control scale; MSQoL: Multiple Sclerosis Quality of Life scale.